NRIX: Bull Flag detected on 2 Sep 2026

NRIX is forming a bull flag pattern with a structure score of 14.2/15, indicating a well-defined consolidation phase following its recent rally. The stock trades at $26.04, nestled between key resistance at $25.08 and support at $21.23, representing a 23.7% margin of safety below the current price. Volume has picked up to 1.23x average (1.32M shares vs. 1.07M 20-day average), supporting pattern authenticity. The breakout score of 11.8/13 and overall quality score of 69.4/98 suggest a credible setup with a 71.94% historical win probability. RSI at 53.48 shows neutral momentum—neither overbought nor oversold. The underlying three-month gain of 59.07% reflects strong prior momentum that now consolidates before a potential breakout.

Nurix entered into a global collaboration with Roche for bexobrutideg with potential total payments of up to $2.3 billion, including a $700 million upfront payment, announced in Q2 2026. The company reported continued execution on a registrational program for bexobrutideg and anticipated multiple clinical and scientific catalysts in 2026. In August 2026, Nurix earned a $10 million milestone payment from Sanofi following initiation of a Phase 1 clinical trial of a STAT6 degrader. Most recently, Nurix announced participation in four September 2026 investor conferences including Wells Fargo (Sept 8), H.C. Wainwright (Sept 14), Baird (Sept 15), and Morgan Stanley (Sept 16). The biotech sector remains in bullish regime (score 0.51), supporting positive sentiment. These catalysts—particularly the Roche partnership validation and pipeline advancement—explain the stock's 59% three-month rally and position the bull flag in a compelling fundamental context.

A successful breakout above the $25.08 resistance would target the conservative measured move of $26.90, implying a 3.3% gain from current levels. Volume confirmation is critical—breakout should sustain volume above 1.1M shares to validate the move. Historical data suggests a 71.94% probability of reaching the target. The invalidation level sits at $21.23 support; a close below this price would signal pattern failure and suggest the consolidation phase reversed into a bearish continuation. The bull flag structure indicates buyers regain control after profit-taking, with the flag representing a pause rather than a reversal of the primary uptrend.

Key risks include clinical trial execution on the lead program bexobrutideg—any Phase 2b/3 setback could trigger sharp reversals. Biotech stocks face inherent regulatory and approval uncertainty. The company still burns cash ($540.7M reported in Feb 2026, down from $592.9M in Nov 2025), though the $700M Roche upfront provides runway. Beta of 0.88 suggests lower systematic risk, but 27.5% annualized volatility (20-day) is elevated for the sector. MACD histogram is negative (-0.2354), signaling weakening upside momentum despite the high RSI neutrality—this divergence warrants caution. No imminent negative catalysts found, but upcoming September conference presentations create near-term event risk. The rounding bottom pattern (180 days, moderate strength) that preceded this flag reduces urgency but also suggests institutional accumulation may be near completion.

We scan more than 6,000 NYSE and NASDAQ stocks every trading day and compare each detected pattern against a database of 370,000+ historical detections. Every setup is scored across three dimensions: Structure, Volume, and Breakout Readiness. Win probability is a calibrated estimate of how similar historical setups performed over the following 10 trading days. This is a swing trading tool built for multi-day holds. It is not built or tested for day trading.